

10 December 2020 EMA/CHMP/330865/2020 - Rev. 2

## Timetable of procedure

Referral under Article 30 of Directive 2001/83/EC

Procedure number: EMEA/H/A-30/1499

Product name: Varilrix and associated names

INN/active substance: live attenuated varicella virus (OKA strain)

Procedural step:	Date:
Notification:	29 May 2020
Start of procedure at CHMP:	25 June 2020
Rapporteur/co-rapporteur assessment reports circulated to CHMP:	14 July 2020
Comments:	16 July 2020
Updated Rapporteur / co-rapporteur assessment reports circulated to CHMP:	17 July 2020
CHMP list of outstanding issues:	23 July 2020
Submission of responses:	22 October 2020
Re-start of the procedure:	12 November 2020
Rapporteur/co-rapporteur joint assessment report circulated to CHMP:	20 November 2020
Comments:	27 November 2020

Official addressDomenico Scarlattilaan 6 • 1083 HS Amsterdam • The NetherlandsAddress for visits and deliveriesRefer to www.ema.europa.eu/how-to-find-usSend us a questionGo to www.ema.europa.eu/contactTelephone +31 (0)88 781 6000



An agency of the European Union

© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.

Procedural step:	Date:
Updated Rapporteur / co-rapporteur joint assessment report circulated to CHMP:	03 December 2020
CHMP list of outstanding issues:	10 December 2020
Submission of responses:	22 January 2021
Re-start of the procedure:	28 January 2021
Rapporteur/co-rapporteur joint assessment report circulated to CHMP:	12 February 2021
Comments:	17 February 2021
Updated Rapporteur / co-rapporteur joint assessment report circulated to CHMP:	19 February 2021
CHMP list of outstanding issues/CHMP opinion:	February 2021 CHMP